The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | RISP: cytisine for smoking cessation in patients over the age of 65
Massimiliano Cani, MD, University of Turin, Turin, Italy, discusses results from the RISP trial (NCT05766046), evaluating the use of cytisine for smoking cessation in older adults over the age of 65. Cytisine is not currently recommended for older adults due to safety concerns, however this study found it to be safe and effective in this population, with a cessation rate comparable to the general population. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
